期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Dissecting the novel abilities of aripiprazole: The generation of anti-colorectal cancer effects by targeting Gαq via HTR2B 被引量:1
1
作者 Haowei Liu Qiuming Huang +3 位作者 Yunqi Fan Bo Li Xuemei Liu Changhua Hu 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2023年第8期3400-3413,共14页
Colorectal cancer(CRC)is a type of malignant tumor that seriously threatens human health and life,and its treatment has always been a difficulty and hotspot in research.Herein,this study for the first time reports tha... Colorectal cancer(CRC)is a type of malignant tumor that seriously threatens human health and life,and its treatment has always been a difficulty and hotspot in research.Herein,this study for the first time reports that antipsychotic aripiprazole(Ari)against the proliferation of CRC cells both in vitro and in vivo,but with less damage in normal colon cells.Mechanistically,the results showed that5-hydroxytryptamine 2B receptor(HTR2B)and its coupling protein G protein subunit alpha q(Gaq)were highly distributed in CRC cells.Ari had a strong affinity with HTR2B and inhibited HTR2B downstream signaling.Blockade of HTR2B signaling suppressed the growth of CRC cells,but HTR2B was not found to have independent anticancer activity.Interestingly,the binding of Gaq to HTR2B was decreased after Ari treatment.Knockdown of Gaq not only restricted CRC cell growth,but also directly affected the antiCRC efficacy of Ari.Moreover,an interaction between Ari and Gaq was found in that the mutation at amino acid 190 of Gaq reduced the efficacy of Ari.Thus,these results confirm that Gaq coupled to HTR2B was a potential target of Ari in mediating CRC proliferation.Collectively,this study provides a novel effective strategy for CRC therapy and favorable evidence for promoting Ari as an anticancer agent. 展开更多
关键词 ARIPIPRAZOLE 5-Hydroxytryptamine receptor 5-Hydroxytryptamine 2B receptor g protein subunit alpha q Colorectal cancer Phosphoinositide 3-kinase/theserine threoninekinaseAKT Extracellularregulated protein kinases
原文传递
鲜红斑痣相关基因及激酶的研究进展
2
作者 迪丽努尔·吾甫尔 丁媛 康晓静 《医学综述》 CAS 2022年第6期1085-1090,共6页
鲜红斑痣是一种体细胞基因突变疾病,这种突变可改变正常血管内皮细胞的功能,导致血管畸形。在大部分鲜红斑痣/Sturge-Weber综合征患者中存在鸟嘌呤核苷酸结合蛋白q多肽(GNAQ)基因体细胞突变位点,且突变与部分临床表现密切相关。推测GNA... 鲜红斑痣是一种体细胞基因突变疾病,这种突变可改变正常血管内皮细胞的功能,导致血管畸形。在大部分鲜红斑痣/Sturge-Weber综合征患者中存在鸟嘌呤核苷酸结合蛋白q多肽(GNAQ)基因体细胞突变位点,且突变与部分临床表现密切相关。推测GNAQ基因突变可作为早期鲜红斑痣的预测因子指导早期干预治疗。RAS p21蛋白激活因子1(RASA1)的体细胞“二次突变”与鲜红斑痣伴发综合征毛细血管-动静脉畸形的发病有关。基因突变引起下游通路中的促分裂原活化的蛋白激酶(MAPK)、磷脂酰肌醇-3-激酶(PI3K)等蛋白激酶活化,参与鲜红斑痣发生的不同阶段。深入研究鲜红斑痣相关GNAQ基因、RASA1基因和MAPK、PI3K等可为其早期诊断及分子治疗提供理论依据。 展开更多
关键词 鲜红斑痣 体细胞突变 鸟嘌呤核苷酸结合蛋白q多肽 RAS p21蛋白激活因子1 促分裂原活化的蛋白激酶 磷脂酰肌醇-3-激酶
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部